Shore Capital Reaffirms Buy Rating for ECO Animal Health Group (LON:EAH)

ECO Animal Health Group (LON:EAH - Get Free Report)'s stock had its "buy" rating restated by research analysts at Shore Capital in a research report issued to clients and investors on Friday, MarketBeat reports.

ECO Animal Health Group Stock Performance

The company has a debt-to-equity ratio of 4.31, a current ratio of 2.96 and a quick ratio of 2.14. The company's 50-day moving average is GBX 74.68 and its 200-day moving average is GBX 101.87. The firm has a market cap of £48.27 million, a P/E ratio of 3,740.00 and a beta of -0.05. ECO Animal Health Group has a 12 month low of GBX 60 ($0.76) and a 12 month high of GBX 135 ($1.72).

ECO Animal Health Group Company Profile

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.